Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study

Table 2

The risk of hospitalization for acute pancreatitis of DPP-4i new users as compared to SU new users.

	N	Events	HR	Lower CI	Upper CI	value
Total patients	26,182	468	0.642	0.535	0.771	<0.001
Patients with underlying CVD	6914	150	0.727	0.527	1.003	0.052
Patients without underlying CVD	19,150	330	0.591	0.476	0.735	<0.001
Male	15,072	287	0.624	0.495	0.788	<0.001
Female	11,100	194	0.600	1.058	0.980	0.116
Patients aged ≥ 65 years	8718	207	0.717	0.545	0.943	0.017
Patients aged < 65 years	17,288	267	0.617	0.485	0.756	<0.001
Patients with DM microvascular complication	4326	91	0.542	0.357	0.822	0.004
Patients without DM microvascular complication	21,740	387	0.622	0.509	0.760	<0.001

CI: 95% confidence interval; CVD: cardiovascular disease; DM: diabetes mellitus; DPP-4i: dipeptidyl-peptidase IV inhibitor; HR: hazard ratio; N: number of patients; SU: sulfonylurea.